Incyte (INCY) Tops Q2 EPS by 6c; Raises Jakafi Sales Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Incyte Reports 2015 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
August 4, 2015 7:00 AM EDT$142 million of 2015 second-quarter net product revenues from Jakafi® (ruxolitinib), representing 69 percent growth over the same period last year 2015 guidance for Jakafi net product revenues increased to range of $560 million to $575 million, driven by strong underlying demand Positive results from two pivotal trials of baricitinib in rheumatoid arthritis presented at EULAR Multiple abstracts presented at ASCO and EHA, demonstrating continued progress across broad clinical portfolio
Conference Call and Webcast Scheduled Today at 10:00 a.m. ET
... More
